Astrazeneca PLC ($AZN) Stock Forecast: Up 5.1% Today

What is Astrazeneca PLC?

AstraZeneca (AZN) Market: AstraZeneca (AZN) had a bullish movement today, driven by positive Q4 earnings and future growth prospects.

Why is Astrazeneca PLC going up?

AZN stock is up 5.1% on Feb 11, 2026 18:43

• AstraZeneca reported strong Q4 earnings, with a 9% product sales growth and a 23.4% operating margin, leading to an upgrade to a Buy rating with a 25% medium-term upside.
• The company's focus on oncology and pipeline developments, aiming for $80 billion in revenues by 2030, has instilled confidence in investors.
• Despite falling slightly short of performance expectations in Q4, the overall positive trajectory of the company's revenue and profit, along with its strategic investments in emerging therapeutic areas like obesity, have contributed to the bullish market movement.
• The company's successful cancer treatments and upcoming Phase III clinical trial readouts further bolstered investor optimism, driving the stock price higher.

AZN Price Chart

AZN Technical Analysis

AZN News

AstraZeneca: Q4 Earnings Analysis - Ticks The Boxes, Upgrading To Buy (AZN)

AstraZeneca reported strong 2025 results with 9% product sales growth and a 23.4% operating margin, along with a dividend increase. The company aims for $80 billion in revenues by 2030, driven by oncology and pipeline developments. Despite upcoming patent expirations for key drugs, new pipeline assets and AI innovations are expected to sustain growth, leading to an upgrade of AZN to Buy with an anticipated 25% medium-term upside.

https://seekingalpha.com/article/4868333-astrazeneca-q4-earnings-analysis-ticks-the-boxes-upgrading-to-buy

Sustained By Cancer Success, AstraZeneca Is Still Sizing Up Obesity Opportunity

AstraZeneca is currently riding a wave of success thanks to its oncology portfolio but is also actively exploring opportunities within the obesity market. The company anticipates a busy year with no fewer than 20 Phase III clinical trial readouts expected. This strategic focus highlights both continued investment in its established strengths and an eye towards emerging therapeutic areas.

https://insights.citeline.com/scrip/business/earnings/sustained-by-cancer-success-astrazeneca-is-still-sizing-up-obesity-opportunity-EKGCEL5EEBA6ZAZMYB4FXUAJVE/

Astrazeneca: Q4 Earnings Snapshot

Astrazeneca (AZN) reported fourth-quarter earnings of $2.33 billion, or 75 cents per share, which adjusted to $1.06 per share. These results, along with revenue of $15.5 billion, fell short of Wall Street expectations. For the full year, the company posted a profit of $10.23 billion on revenue of $58.74 billion, with its stock climbing 2.5% year-to-date and 31% over the past 12 months.

https://www.kens5.com/article/syndication/associatedpress/astrazeneca-q4-earnings-snapshot/616-bda9b05c-7576-4483-8d17-6f0db738a38f

Astrazeneca: Q4 Earnings Snapshot

Astrazeneca PLC reported fourth-quarter earnings of $2.33 billion, or 75 cents per share, which adjusted for non-recurring costs, amounted to $1.06 per share. These results, along with revenue of $15.5 billion, missed Wall Street expectations. For the full year, the company posted a profit of $10.23 billion on revenue of $58.74 billion, with its shares having climbed 2.5% year-to-date and 31% over the last 12 months.

https://www.kare11.com/article/syndication/associatedpress/astrazeneca-q4-earnings-snapshot/616-bda9b05c-7576-4483-8d17-6f0db738a38f

Earnings Flash (AZN.L) AstraZeneca PLC Posts FY25 EPS $6.54

AstraZeneca PLC has reported its fiscal year 2025 earnings per share (EPS) of $6.54. This release is part of a broader set of announcements from the company, including its full-year revenue of $58.74 billion, and reflects general growth with positive analyst ratings from various financial institutions.

https://www.marketscreener.com/news/earnings-flash-azn-l-astrazeneca-plc-posts-fy25-eps-6-54-ce7e5adfdc8bf426

Trending Today

BlackBerry Limited ($BB) Stock Forecast: Down 6.0% Today

NASDAQ-100 ($NDX) Index Forecast: Down 0.7% Today

Brent Crude Oil ($BRENT) Commodity Forecast: Up 5.3% Today

Crude Oil ($CRUDE) Commodity Forecast: Up 5.1% Today

S&P 500 Index ($SPX) Index Forecast: Down 0.6% Today

Binance Coin ($BNB) Crypto Forecast: Up 3.7% Today

Dogecoin ($DOGE) Crypto Forecast: Up 5.1% Today

Astrazeneca PLC Price History

11.01.2026 - AZN Stock was up 5.1%

• AstraZeneca reported strong Q4 earnings, with a 9% product sales growth and a 23.4% operating margin, leading to an upgrade to a Buy rating with a 25% medium-term upside.
• The company's focus on oncology and pipeline developments, aiming for $80 billion in revenues by 2030, has instilled confidence in investors.
• Despite falling slightly short of performance expectations in Q4, the overall positive trajectory of the company's revenue and profit, along with its strategic investments in emerging therapeutic areas like obesity, have contributed to the bullish market movement.
• The company's successful cancer treatments and upcoming Phase III clinical trial readouts further bolstered investor optimism, driving the stock price higher.

05.00.2026 - AZN Stock was down 1.3%

• Institutional investors are increasingly acquiring shares of AstraZeneca PLC, signaling confidence in the company's future and financial performance.
• AstraZeneca recently posted positive quarterly earnings, with analysts giving it a "Moderate Buy" rating; however, the stock saw a bearish movement, likely due to profit-taking or shifting market sentiment.
• Various wealth management firms have collectively increased their stock holdings in AstraZeneca, indicating a positive long-term outlook despite the recent bearish trend.
• The stock's downturn today may be influenced by industry trends or broader macroeconomic factors affecting the pharmaceutical sector.

02.01.2026 - AZN Stock was down 0.4%

• Reduction of stake by Federated Hermes Inc. by 23.9% might have indicated a lack of confidence in the company's future performance.
• Despite strong quarterly earnings and strategic moves, the bearish movement could be linked to profit-taking by investors following a positive period.
• Transition to a harmonized global listing on the NYSE and the EU recommendation for Imfinzi may have initially uplifted investor sentiment but the market may have reacted adversely due to various factors.
• Shift from Nasdaq to the NYSE and positive news on Imfinzi could have initially excited investors, but some may have taken the opportunity to sell and secure profits, leading to the bearish movement.

06.00.2026 - AZN Stock was up 5.3%

• Institutional investors like My Personal CFO LLC, Moody Lynn & Lieberson LLC, and Smith Salley Wealth Management have been acquiring significant stakes in AstraZeneca, signaling confidence in the company's future prospects.
• AstraZeneca's recent strong quarterly earnings results, with EPS of $1.19 and revenue of $15.19 billion, have impressed analysts and investors alike, leading to a positive market sentiment towards the stock.
• The company's focus on R&D spend, robust pipeline, and global presence has positioned it as a strong contender for long-term growth, attracting investors looking for stability and diversified growth opportunities.
• The overall positive outlook for AstraZeneca, coupled with increased institutional investments and strong financial performance, has likely contributed to the bullish movement in the stock today.